Single cord blood transplantation in Japan; expanding the possibilities of CBT

Yamamoto, Hisashi

doi:10.1007/s12185-019-02672-4

Cited by 33 publications

(16 citation statements)

References 68 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The introduction of CBT has expanded access to allogeneic HCT for adults who need urgent HCT worldwide, and by the end of 2016, nearly 50 000 CB units had been released by public banks for allogeneic HCT . In Japan, the cumulative number of CBT for children and adults reached 15 544 in 2017 . The strength of our study was the largest sample size of adult single‐unit CBT, which included nearly all CBT as the first allogeneic HCT for adults in Japan.…”

Section: Discussionmentioning

confidence: 99%

Improvement of early mortality in single‐unit cord blood transplantation for Japanese adults from 1998 to 2017

Konuma

Kanda

Inamoto³

et al. 2020

American J Hematol

View full text Add to dashboard Cite

The major limitation of cord blood transplantation (CBT) for adults remains the delayed hematopoietic recovery and higher incidence of graft failure, which result in a higher risk of early mortality in CBT. We evaluated early overall survival (OS), non‐relapse mortality (NRM), neutrophil engraftment, acute graft‐vs‐host disease, and cause of early death among 9678 adult patients who received single‐unit CBT in Japan between 1998 and 2017. The probability of OS at 100 days was 64.4%, 71.7%, and 78.9% for the periods 1998 to 2007, 2008 to 2012, and 2013 to 2017, respectively (P < .001). The cumulative incidences of NRM at 100 days during the same period were 28.3%, 20.8%, and 14.6%, respectively (P < .001). The cumulative incidences of neutrophil engraftment were also improved during the same period (P < .001). The most common cause of death within 100 days after CBT was bacterial infection in 1998 to 2007 and primary disease in the latter two time periods. Across the three time periods, the proportions of deaths from bacterial and fungal infection, graft failure, hemorrhage, sinusoidal obstructive syndrome, and organ failure decreased in a stepwise fashion. Landmark analysis of OS and NRM after 100 days showed that OS did not change over time in the multivariate analysis. Our registry‐based data demonstrated a significant improvement of early OS after CBT for adults over the past 20 years. The landmark analysis suggested that improvement of early mortality could lead to an improvement of long‐term OS after CBT.

show abstract

Section: Discussionmentioning

confidence: 99%

Improvement of early mortality in single‐unit cord blood transplantation for Japanese adults from 1998 to 2017

Konuma

Kanda

Inamoto³

et al. 2020

American J Hematol

View full text Add to dashboard Cite

show abstract

“…13 In Japan, almost all CBTs have used the grafts from single donors, but not multiple donors, as previously described. 17 Accordingly, all the grafts of cord blood as well as those of bone marrow and peripheral blood stem cells (PBSCs) were sourced from single donors, following the Japan Cord Blood Bank Network/ Japanese Marrow Donor Program standard. 17 Most PBSCs were stored as cryopreserved products using DMSO alone or freezing medium (CP-1, Kyokuto Pharmaceutical), which contains DMSO and hydroxyethyl starch (HES).…”

Section: Hematopoietic Cell Preparation Infusion and Monitoring Of mentioning

confidence: 99%

“…Kazuhiko Ikeda , 1,2 Hitoshi Ohto, 1,2 Minami Yamada-Fujiwara, 1,3 Yoshiki Okuyama, 1,4 Shin-ichiro Fujiwara , 1,5 Kazuo Muroi, 1,6 Takehiko Mori, 7 Kinuyo Kasama, 8 Heiwa Kanamori, 1,9 Tohru Iseki, 1,10 Tokiko Nagamura-Inoue, 1,11 Kazuaki Kameda, 12 Junya Kanda, 13 Kazuhiro Nagai, 14 Nobuharu Fujii, 15 Takashi Ashida, 16 Asao Hirose, 17 Tsutomu Takahashi, 18 Keiji Minakawa, 2 and Ryuji Tanosaki 1 BACKGROUND: Hematopoietic cell infusion-related adverse events (HCI-AEs) in hematopoietic stem cell transplantations (HSCTs) have been largely attributed to toxicity of dimethyl sulfoxide (DMSO) for cryopreservation, but HSC products also contain various cells and plasma components. Our recent prospective study of 1125 HSCT recipients revealed the highest overall HCI-AE rate in bone marrow transplantation (BMT) using fresh/noncryopreserved products, although products of peripheral blood stem cell transplantation and cord blood transplantation (CBT) are generally cryopreserved with DMSO containing smaller plasma volumes.…”

mentioning

confidence: 99%

Hematopoietic cell infusion‐related adverse events in pediatric/small recipients in a prospective/multicenter study

et al. 2020

View full text Add to dashboard Cite

BACKGROUND Hematopoietic cell infusion‐related adverse events (HCI‐AEs) in hematopoietic stem cell transplantations (HSCTs) have been largely attributed to toxicity of dimethyl sulfoxide (DMSO) for cryopreservation, but HSC products also contain various cells and plasma components. Our recent prospective study of 1125 HSCT recipients revealed the highest overall HCI‐AE rate in bone marrow transplantation (BMT) using fresh/noncryopreserved products, although products of peripheral blood stem cell transplantation and cord blood transplantation (CBT) are generally cryopreserved with DMSO containing smaller plasma volumes. We aimed to clarify if product volume and component effects are more substantial in small recipients including children. STUDY DESIGN AND METHODS We performed subgroup analysis on 219 recipients of 45 kg or less body weight (whole small recipients), including 90 children (pediatric recipients), from the original cohort (general recipients). RESULTS Whereas overall HCI‐AE rates did not differ among hematopoietic stem cell sources in the general recipients, bradycardia most often occurred after CBT in whole small recipients. Conversely, whole small and general recipients shared the same trend of having the highest rate of hypertension in BMT. The overall HCI‐AE rate was higher in allogeneic HSCT compared with autologous HSCT. Notably, pediatric recipients showed a 10‐fold higher incidence of nausea and vomiting in allogeneic HSCT compared with autologous HSCT, suggesting a possible role of allogeneic antigens. Multivariate analysis identified a relatively large infusion volume per body weight as a significant factor correlating with HCI‐AE in whole small recipients. CONCLUSIONS We should be aware of product volume and specific HCI‐AEs such as nausea and vomiting in small patients including children.

show abstract

“…Cord blood would be used as an alternative when adult donor is not readily available in many transplant centers. The issue of relatively low stem cell dose for adult size recipient has been resolved by the application of double cord blood units, and has been proven success clinically (48,49). Whether cord blood can eventually substitute the need of a large registry is still debatable.…”

Section: Resultsmentioning

confidence: 99%

Revisit of Optimal Donor Number Estimation in the Hong Kong Bone Marrow Donor Registry

Cheung

Lui

et al. 2021

Front. Immunol.

View full text Add to dashboard Cite

High resolution typing of the HLA-DPB1 locus for patient who requested for hematopoietic stem cell transplantation (HSCT) workup has recently become mandatory by the National Marrow Donor Program (NMDP) in order to facilitate matching between donors and recipients for better outcomes. The likelihood of identifying HLA matched donors in Hong Kong, on top of the existing HLA-A, -B, -C, and -DRB1 loci, is revisited in this study. HLA-A, -B, -C, -DRB1 and -DPB1 genotypes of 5,266 volunteer unrelated Chinese donors from the Hong Kong Bone Marrow Donor Registry (HKBMDR), were included in this study. Matching models were employed to determine the matching probabilities for 10/10(DPB1) and 9/10(DPB1) HLA match. The matching probabilities are 20% at 10/10(DPB1) HLA match and 55% at 9/10(DPB1) match, based on the existing 130,000 donors in the HKBMDR. The likelihoods of match become 27% and 65% respectively, by increasing the registry to 250,000. However, if DPB T-cell-epitope (TCE) model is considered in the matching, the probability will increase to 46% at 10/10 DPB1 permissive mismatching. Our findings provide vital information about the future planning on the targeted recruitment size, HLA typing and search strategies of the donor registry and arose the transplant physicians’ acceptability to 9/10(DBP1) or 10/10(DBP1) HLA match. Nevertheless, the marrow donor registry has planned for increasing the registry size and bringing down the age of recruited donors which will ultimately enhance patient outcome.

show abstract

Single cord blood transplantation in Japan; expanding the possibilities of CBT

Cited by 33 publications

References 68 publications

Improvement of early mortality in single‐unit cord blood transplantation for Japanese adults from 1998 to 2017

Improvement of early mortality in single‐unit cord blood transplantation for Japanese adults from 1998 to 2017

Hematopoietic cell infusion‐related adverse events in pediatric/small recipients in a prospective/multicenter study

Revisit of Optimal Donor Number Estimation in the Hong Kong Bone Marrow Donor Registry

Contact Info

Product

Resources

About